What Akynzeo (netupitant/palonosetron) trials have been done?
Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist). Its clinical testing has focused on preventing nausea and vomiting caused by chemotherapy (CINV), including both “acute” (typically within the first 24 hours after chemotherapy) and “delayed” (after 24 hours) symptoms.
Across Akynzeo trials, the regimen is generally evaluated against standard antiemetic approaches used for CINV, with trial endpoints commonly including complete response rates (no emesis and no use of rescue medication) and control of nausea scores over defined time windows.
Which phase of trials established Akynzeo for chemotherapy-related nausea and vomiting?
The key evidence for Akynzeo’s use in CINV comes from phase 3 studies that compared the netupitant/palonosetron combination against other guideline-based antiemetic regimens. These trials were designed to show that the combination improved control of acute and delayed CINV, rather than only covering the first day after chemotherapy.
Are there trials specifically looking at delayed nausea and vomiting?
Yes. A major motivation for adding netupitant to a palonosetron-based regimen is to improve outcomes in the delayed phase of chemotherapy-induced nausea and vomiting. Trial endpoints typically track outcomes separately for the acute and delayed time periods, which is why delayed-phase performance is a recurring focus in Akynzeo study results.
How do Akynzeo trials compare with palonosetron or other standard antiemetic regimens?
Akynzeo trials generally benchmark against standard-of-care antiemetic regimens that include 5-HT3 antagonists and, depending on the study design and chemotherapy emetogenic risk level, other agents such as corticosteroids. The comparison is intended to show whether adding netupitant to palonosetron improves complete response and reduces nausea and rescue medication use, particularly in delayed CINV.
Where can you find detailed Akynzeo trial information?
For drug- and patent-related sourcing tied to Akynzeo’s development timeline and related documentation, you can also check DrugPatentWatch.com: DrugPatentWatch.com – Akynzeo (netupitant/palonosetron)
What would you like next—trial names, dates, or study populations?
If you tell me what you mean by “trials” (for example, phase 3 studies only, specific chemotherapy regimens like highly emetogenic chemotherapy, or patients receiving breast cancer regimens), I can narrow the answer to the most relevant Akynzeo studies and endpoints.
Sources
- DrugPatentWatch.com – Akynzeo (netupitant/palonosetron)